PR83579

DARMSTADT, Germany, Apr. 7, 2020 /PRNewswire=KYODO JBN/--

-- CRISPR-chrom technology improves access to genome for more efficient

editing

-- Only U.S. patent holder in the CRISPR chromatin space

-- Company driving innovation in CRISPR gene-editing technologies

Merck, a leading science and technology company, today announced that the

United States Patent and Trademark Office has granted the company's patent for

CRISPR-chrom technology. With this allowance, Merck is the only provider with a

patent covering the fusion of chromatin modulating peptides to CRISPR proteins,

helping to clear chromatin out of the way, increasing access to the genome.

Photo - https://mma.prnewswire.com/media/1141070/Merck.jpg

"This award marks our second U.S. CRISPR patent and our 23rd CRISPR-related

patent worldwide, and as a leading innovator of CRISPR technology, we will

continue to drive innovation and collaborate with scientists around the world

to ensure that they have the most advanced gene-editing options," said Udit

Batra, member of the Merck Executive Board and CEO, Life Science.

Because genomic DNA in mammalian cells is wrapped tightly in protein complexes

called chromatin, the genomic DNA is often inaccessible to CRISPR. Merck's

CRISPR-chrom technology works by fusing chromatin modulating peptides to a

CRISPR protein, Cas9 (i.e., CRISPR's DNA scissors), allowing for more efficient

gene editing. This work was initially published in the February 2018 issue of

The CRISPR Journal (

https://c212.net/c/link/?t=0&l=en&o=2768284-2&h=4290016811&u=https%3A%2F%2Fwww.liebertpub.com%2Fdoi%2Ffull%2F10.1089%2Fcrispr.2018.0036%3Furl_ver%3DZ39.88-2003%26rfr_id%3Dori%3Arid%3Acrossref.org%26rfr_dat%3Dcr_pub%253dpubmed&a=published+in+the+February+2018+issue+of+The+CRISPR+Journal

) and was one of the journal's top five downloaded articles of the year.

The Life Science business of Merck, a leader in genome editing, conducts

research and development to drive improvements in gene-editing technologies.

The company's CRISPR patent portfolio includes granted patents for

CRISPR-related technologies covering foundational and alternative

genome-editing methods. Patents for the company's CRISPR integration technology

have been granted in Australia, Canada, China, Europe, Israel, Singapore and

South Korea. Patents granted in Europe and pending elsewhere cover plasmid or

viral vectors encoding CRISPR systems, which are necessary to perform genome

modification in eukaryotic cells. Other European patents and pending

applications are for protein-RNA nickase compositions.

Merck received its first U.S. patent in February 2019 for its proxy-CRISPR

technology, which makes CRISPR more efficient, flexible and specific. The

company has successfully out-licensed its CRISPR patent portfolio and continues

to license its entire CRISPR patent portfolio for all fields of use. Merck is

proactively and aggressively pursuing CRISPR patent out-licensing partners for

therapeutics, agriculture and research and welcome such collaboration

opportunities.

CRISPR technology is a core competency for Merck, which has 16 years'

experience with genome editing, spanning from discovery to manufacturing. The

company develops technologies in a range of genome-editing applications,

including gene knockout, gene integration and CRISPR libraries for genetic

screens, among others.

Merck recognizes that genome editing has resulted in major advancements in

biological research and medicine. At the same time, the growing potential of

genome-editing technologies has opened scientific, legal and societal concerns.

The company supports research with genome editing under careful consideration

of ethical and legal standards. Merck has established an independent, external

Bioethics Advisory Panel (

https://c212.net/c/link/?t=0&l=en&o=2768284-2&h=2989328645&u=https%3A%2F%2Fwww.merckgroup.com%2Fen%2Fcr-report%2F2018%2Fbusiness-ethics%2Fbioethics.html&a=Bioethics+Advisory+Panel

) to provide guidance for research in which its businesses are involved,

including research on or using genome editing, and has developed, defined and

transparently published a clear operational position (

https://c212.net/c/link/?t=0&l=en&o=2768284-2&h=253148026&u=https%3A%2F%2Fwww.merckgroup.com%2Fcontent%2Fdam%2Fweb%2Fcorporate%2Fnon-images%2Fcompany%2Fresponsibility%2Fen%2Fregulations-and-guidelines%2Fgenome-editing-principle-EN.pdf&a=position

) taking into account scientific and societal issues to inform promising

therapeutic approaches for use in research and applications.

All Merck news releases are distributed by email at the same time they become

available on the Merck Website. Please go to www.merckgroup.com/subscribe to

register online, change your selection or discontinue this service.

About Merck

Merck, a leading science and technology company, operates across healthcare,

life science and performance materials. Around 57,000 employees work to make a

positive difference to millions of people's lives every day by creating more

joyful and sustainable ways to live. From advancing gene editing technologies

and discovering unique ways to treat the most challenging diseases to enabling

the intelligence of devices -- the company is everywhere. In 2019, Merck

generated sales of EUR16.2 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to

Merck's technological and scientific advances. This is how Merck has thrived

since its founding in 1668. The founding family remains the majority owner of

the publicly listed company. Merck holds the global rights to the Merck name

and brand. The only exceptions are the United States and Canada, where the

business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma

in life science and EMD Performance Materials.

SOURCE: Merck

CONTACT: Gangolf.schrimpf@merckgroup.com, Phone: 01 6151 72-5577